Sigma-1 receptor antagonists, including compound 3, are primarily investigated for their potential therapeutic applications in neurological and psychiatric disorders. These compounds are studied for their ability to modulate the sigma-1 receptor, which plays a role in regulating cellular stress responses, neurotransmission, and neuroplasticity. Research suggests that sigma-1 receptor antagonists may be beneficial in treating conditions such as depression, anxiety, and neuropathic pain. Additionally, they are being explored for their potential in managing neurodegenerative diseases like Alzheimer's and Parkinson's by influencing protein misfolding and oxidative stress pathways. In cancer research, these antagonists are being examined for their role in inhibiting tumor growth and enhancing the efficacy of chemotherapy drugs. Their application in drug addiction treatment is also under investigation, as they may help reduce dependency and withdrawal symptoms. Overall, sigma-1 receptor antagonists represent a promising area of study for developing novel treatments across a range of medical conditions.